An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease

References

• Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol. 2006;26(4):261–268.
   PubMed Web of Science ®Google Scholar
• Chiang CK, Tanaka T, Inagi R, et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011;91(11):1564–1571.
   PubMed Web of Science ®Google Scholar
• Nangaku M, Mimura I, Yamaguchi J, et al. Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients. J Ren Nutr. 2015;25(2):160–163.
   PubMed Web of Science ®Google Scholar
• Mimura I, Tanaka T, Nangaku M. How the target hemoglobin of renal anemia should be. Nephron. 2015;131(3):202–209.
   PubMed Web of Science ®Google Scholar
• Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1077–1083.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–798.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–1155.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017;92(2):306–312.
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(5):331–338.
   PubMed Web of Science ®Google Scholar
• Sakashita M, Tanaka T, Nangaku M. Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease. Contrib Nephrol. 2019;198:112–123.
   PubMed Web of Science ®Google Scholar
• Kurata Y, Tanaka T, Nangaku M. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2020;29(4):414–422.
   PubMed Web of Science ®Google Scholar
• Groenendaal-Van de Meent D, Adel MD, Noukens J, et al. Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin Drug Investig. 2016;36(9):743–751.
   PubMed Web of Science ®Google Scholar
• Shibata T, Nomura Y, Takada A, et al. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non‐elderly healthy adult male subjects. J Clin Pharm Ther. 2018;43(5):633–639.
   PubMed Web of Science ®Google Scholar
• Groenendaal-van de Meent D, den Adel M, van Dijk J, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, safety, and tolerability of roxadustat in healthy subjects. Eur J Drug Metab Pharmacokinet. 2018;43(6):685–692.
   PubMed Web of Science ®Google Scholar
• Groenendaal-Van de Meent D, Kerbusch V, Kaspera R, et al. Effect of kidney function and dialysis on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Eur J Drug Metab Pharmacokinet. 2021;46(1):141–153.
   PubMed Web of Science ®Google Scholar
• Groenendaal-Van de Meent D, Kerbusch V, Barroso-Fernandez B, et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021;43(6):1079–1091. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Agency PaMD. Report on the deliberation results for roxadustat. [cited 2021 Aug 3 https://www.pmda.go.jp/files/000234811.pdf
   Google Scholar
• Groenendaal-van de Meent D, den Adel M, Rijnders S, et al. The hypoxia-inducible factor Prolyl-Hydroxylase inhibitor roxadustat (FG-4592) and Warfarin in healthy volunteers: a pharmacokinetic and pharmacodynamic drug-drug interaction study. Clin Ther. 2016;38(4):918–928.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Tumlin J, Zabaneh R, et al. Oral hypoxia‐inducible factor prolyl hydroxylase inhibitor roxadustat (FG‐4592) for treatment of anemia in chronic kidney disease: a Placebo‐Controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients. J Clin Pharmacol. 2020;60(11):1432–1440.
   PubMed Web of Science ®Google Scholar
• Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS ONE. 2014;9(11):e111838.
   PubMed Web of Science ®Google Scholar
• Barrett TD, Palomino HL, Brondstetter TI, et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015;172(16):4078–4088.
   PubMed Web of Science ®Google Scholar
• Fukui K, Shinozaki Y, Kobayashi H, et al. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-alpha protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. Eur J Pharmacol. 2019;859:172532.
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151–2156.
   PubMed Web of Science ®Google Scholar
• Querbes W, Bogorad RL, Moslehi J, et al. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood. 2012;120(9):1916–1922.
   PubMed Web of Science ®Google Scholar
• Souma T, Nezu M, Nakano D, et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol. 2016;27(2):428–438.
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Kaelin WG. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329(5990):407.
   PubMed Web of Science ®Google Scholar
• Hoppe G, Yoon S, Gopalan B, et al. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. Proc Nat Acad Sci. 2016;113(18):E2516–E2525.
   PubMed Web of Science ®Google Scholar
• Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009;119(5):1159–1166.
   PubMed Web of Science ®Google Scholar
• Van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. 2020;16:77–98.
   PubMed Web of Science ®Google Scholar
• Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Investig. 2012;122(12):4635–4644.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–684.
   PubMed Web of Science ®Google Scholar
• Hanudel MR, Wong S, Jung G, et al. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. Kidney Int. 2021;100(1):79–89.
   PubMed Web of Science ®Google Scholar
• Coffey R, Sardo U, Kautz L, et al. Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice. Physiol Rep. 2018;6(19):e13890.
   PubMed Web of Science ®Google Scholar
• Del Balzo U, Signore PE, Walkinshaw G, et al. Nonclinical characterization of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat, a novel treatment of anemia of chronic kidney disease. J Pharmacol Exp Ther. 2020;374(2):342–353.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016;11(6):982–991.
   PubMed Web of Science ®Google Scholar
• Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8):1373–1386.
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Otsuka T, et al. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, Placebo-Controlled trial. Adv Ther. 2019;36(6):1438–1454.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus Epoetin Alfa for anemia in patients receiving maintenance hemodialysis: a Phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912–924.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Peng X, et al., Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11): 1001–1010.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Roger SD, Shin SK, et al., Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6(3): 624–635.
   PubMed Web of Science ®Google Scholar
• Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al., Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized Phase 3 study. J Am Soc Nephrol. 2021;32(3): 737–755.
   PubMed Web of Science ®Google Scholar
• Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (Alps). Nephrol Dialysis Transplantation. 2021;36(9):1629–1639. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrol Dialysis Transplantation. 2021;36(9):1616–1628. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Otsuka T, et al., POS-244 A Phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in Non-Dialysis-Dependent (NDD) patients with anemia in Chronic Kidney Disease (CKD). Kidney Int Rep. 2021;6(4): S103.
   Google Scholar
• Chen N, Hao C, Liu BC, et al., Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11): 1011–1022.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Yamaguchi Y, et al., Phase 3, randomized, double-blind, active-comparator (Darbepoetin Alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7): 1628–1639.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Pollock CA, and El-Shahawy MA, et al. ROCKIES: an international, Phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract TH-OR022]. J Am Soc Nephrol. 2019 30 ;6.
   Google Scholar
• Provenzano R, Evgeny S, and Liubov E, et al. Himalayas: a Phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract TH-OR021]. J Am Soc Nephrol. 2019 30 ;5.
   Google Scholar
• Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS Study. Kidney Int Rep. 2021;6(7): 1829–1839.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Yamaguchi Y, Otsuka T, et al. A Phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients not on dialysis. Nephron. 2020;144(8):372–382.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Otsuka T, Reusch M, et al. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, Phase 3, multicenter, open-label study. Ther Apher Dial. 2020;24(2):115–125.
   PubMed Web of Science ®Google Scholar
• Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27(4):1225–1233.
   PubMed Web of Science ®Google Scholar
• Esposito C, Csiky B, and Tataradze A, et al. Two Phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (Alps) dialysis [abstract SA-PO225]. J Am Soc Nephrol. 2019 30 ;822.
   Google Scholar
• Ganz T. Anemia of Inflammation. N Engl J Med. 2019;381(12):1148–1157.
   PubMed Web of Science ®Google Scholar
• Rosati A, Ravaglia F, Panichi V. improving erythropoiesis stimulating agent hyporesponsiveness in hemodialysis patients: the role of hepcidin and hemodiafiltration online. Blood Purif. 2018;45(1–3):139–146.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Yamaguchi Y, Majikawa Y, et al. 2020. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis and Dialysis, Online ahead of print. ;.
   Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Meadowcroft AM, Maier R, et al. Four-Week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234–1244.
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Akizawa T, Nangaku M, et al. A 24-week anemia correction study of Daprodustat in Japanese dialysis patients. Ther Apher Dial. 2020;24(2):108–114.
   PubMed Web of Science ®Google Scholar
• Parmar DV, Kansagra KA, Patel JC, et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a Phase 2 study. Am J Nephrol. 2019;49(6):470–478.
   PubMed Web of Science ®Google Scholar
• Shen GM, Zhao YZ, Chen MT, et al. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J. 2012;441(2):675–683.
   PubMedGoogle Scholar
• Hwang S, Nguyen AD, Jo Y, et al. Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem. 2017;292(22):9382–9393.
   PubMed Web of Science ®Google Scholar
• Saito H, Tanaka T, Sugahara M, et al., Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. Lab Invest. 2019;99(8): 1217–1232.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Y, Wang P, et al. Adipocyte hypoxia-inducible factor 2alpha suppresses atherosclerosis by promoting adipose ceramide catabolism. Cell Metab. 2019;30(5):937–951 e935.
   PubMed Web of Science ®Google Scholar
• Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25.
   PubMed Web of Science ®Google Scholar
• Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010;6(11):667–678.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol. 2013;9(4):211–222.
   PubMed Web of Science ®Google Scholar
• Wakashima T, Tanaka T, Fukui K, et al. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors. Am J Physiol Renal Physiol. 2020;318(1):F14–F24.
   PubMed Web of Science ®Google Scholar
• Ito M, Tanaka T, Ishii T, et al., Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage. Kidney Int. 2020;97(4): 687–701.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Tanaka S, Tanaka T, et al., Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J Am Soc Nephrol. 2020;31(3): 560–577.
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Tanaka T, Saito T, et al., The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int. 2020;97(5): 934–950.
   PubMed Web of Science ®Google Scholar
• FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program. [cited 2021 Aug 3 https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-topline-results-pooled-safety
   Google Scholar
• Provenzano R, Fishbane S, Szczech L, et al. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis. Kidney Int Rep. 2021;6(3):613–623.
   PubMed Web of Science ®Google Scholar
• FibroGen Provides Additional Information on Roxadustat. [cited 2021 Aug 3 https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-provides-additional-information-roxadustat
   Google Scholar
• UPDATED TIME INFORMATION. July 15, 2021. Meeting of the cardiovascular and renal drugs advisory committee meeting announcement. [cited 2021 Aug 3 https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-information-july-15-2021-meeting-cardiovascular-and-renal-drugs-advisory-committee#event-information
   Google Scholar
• Akizawa T, Ueno M, Shiga T, et al.Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies.Therapeutic Apheresis and Dialysis.2020;24:628–641. 6
   PubMed Web of Science ®Google Scholar
• McGettrick AF, O’Neill LAJ. The Role of HIF in Immunity and Inflammation. Cell Metab. 2020;32(4):524–536.
   PubMed Web of Science ®Google Scholar
• Schaible B, Mcclean S, Selfridge A, et al. Hypoxia modulates infection of epithelial cells by pseudomonas aeruginosa. PLoS ONE. 2013;8(2):e56491.
   PubMed Web of Science ®Google Scholar
• Hams E, Saunders SP, Cummins EP, et al. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells. Shock. 2011;36(3):295–302.
   PubMed Web of Science ®Google Scholar
• Seeley TW, Sternlicht MD, Klaus SJ, et al. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia. 2017;5:1–9.
   PubMed Web of Science ®Google Scholar
• Nishide S, Matsunaga S, Shiota M, et al. Controlling the phenotype of tumor-infiltrating macrophages via the PHD-HIF axis inhibits tumor growth in a mouse model. iScience. 2019;19:940–954.
   PubMed Web of Science ®Google Scholar
• Mokas S, Lariviere R, Lamalice L, et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. Kidney Int. 2016;90(3):598–609.
   PubMed Web of Science ®Google Scholar
• Kraus A, Peters DJM, Klanke B, et al. HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94(5):887–899.
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Roy J, Tao K, et al. Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. J Am Soc Nephrol. 2016;27(3):877–886.
   PubMed Web of Science ®Google Scholar
• Cowburn AS, Crosby A, Macias D, et al. HIF2alpha-arginase axis is essential for the development of pulmonary hypertension. Proc Natl Acad Sci U S A. 2016;113(31):8801–8806.
   PubMed Web of Science ®Google Scholar
• Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139–148.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Cizman B, Meadowcroft AM, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12(1):129–138.
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Agarwal R, Aswad A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384(17):1601–1612.
   PubMed Web of Science ®Google Scholar
• Yap DYH, Mcmahon LP, Hao CM, et al. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology. 2021;26(2):105–118.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cai X, Ni J, et al. Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat. Int J Lab Hematol. 2020;42(6):e291–293.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease Who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–590.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of Darbepoetin Alfa in type 2 diabetes and chronic kidney disease. New England. J Med. 2009;361:2019–2032.
   Google Scholar
• Tang X, Fang M, Cheng R, et al. Iron-Deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability. Circ Res. 2020;127(5):651–663.
   PubMed Web of Science ®Google Scholar
• Chang Y-L, Hung S-H, Ling W, et al. Association between ischemic stroke and iron-deficiency anemia: a population-based study. PLoS ONE. 2013;8(12):e82952.
   PubMed Web of Science ®Google Scholar
• Park MJ, Park PW, Seo YH, et al. The relationship between iron parameters and platelet parameters in women with iron deficiency anemia and thrombocytosis. Platelets. 2013;24(5):348–351.
   PubMed Web of Science ®Google Scholar